Past Events
Neuralstem, Inc. at the 2011 World Stem Cell Summit
Additional Information:
Expert Luncheon: "The long and winding road: Neuralstem's ALS clinical trial"
Pasadena, CA
Additional Information:
Expert Luncheon: "The long and winding road: Neuralstem's ALS clinical trial"
Pasadena, CA
ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also ... |